Drugs / QLS32015
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07185477 | Sep 2025 → May 2027 expected | refractory plasma cell neoplasm | Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT05920876 | Jun 2023 → Dec 2024 | refractory plasma cell neoplasm | Qilu Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07018050 | Sep 2025 → Nov 2027 expected | refractory plasma cell neoplasm | Qilu Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07138209 | Nov 2025 → Dec 2027 expected | refractory plasma cell neoplasm | Qilu Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QLS32015 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05920876 ↗ |
| Route | Subcutaneous | “Participants will receive subcutaneous (SC) injection of QLS32015.” NCT05920876 ↗ |
| Target | GPRC5D | “targeting G protein-coupled receptor family C group 5-member D (GPRC5D)” NCT05920876 ↗ |